Please try another search
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Name | Age | Since | Title |
---|---|---|---|
Douglas V. Faller | - | - | Scientific Founder & Chairman of Scientific Advisory Board |
Ivor Royston | 78 | 2007 | Director |
Thomas Eric Darcy | 73 | 2021 | Independent Director |
Stephen Rubino | 66 | 2021 | Independent Director |
Barry J. Simon | 59 | 2021 | Independent Director |
Mark Andrew Rothera | 61 | 2022 | CEO, President & Director |
Roger James Pomerantz | 67 | 2020 | Independent Chairman of the Board |
Robert Baiocchi | - | 2018 | Member of Scientific Advisory Board |
Ronald Levy | - | 2018 | Member of Scientific Advisory Board |
Jane F. Barlow | 63 | 2021 | Independent Director |
Daniel Douglas Von Hoff | 76 | - | Member of Scientific Advisory Board |
Lawrence S. Young | - | 2018 | Member of Scientific Advisory Board |
Pierluigi Porcu | - | 2018 | Member of Scientific Advisory Board |
Flavia Borellini | 65 | 2021 | Independent Director |
Samuel Lafayette Murphy | 46 | 2019 | Independent Director |
Carl H. June | 70 | 2018 | Member of Scientific Advisory Board |
Gavin Giovannoni | - | 2024 | Member of Scientific Advisory Board |
Shannon Kenney | - | - | Member of Scientific Advisory Board |
Jane Chung | 52 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review